I-BET-762: Selective BET Inhibitor for Epigenetic and Inflammation Research

Executive Summary: I-BET-762 (SKU: B1498) is a potent, selective inhibitor of BET family proteins, binding with nanomolar affinity to the acetyl-lysine binding pocket (IC50: 32.5–42.5 nM; Kd: 50.5–61.3 nM) [product]. It competitively displaces acetyl-lysine residues, resulting in downregulation of LPS-inducible cytokine and chemokine gene expression in vitro and in vivo (Fan et al., 2024). In cancer models, I-BET-762 enhances erastin-induced ferroptosis by increasing reactive oxygen species (ROS) and downregulating FSP1, with cell line-specific transcriptional effects [DOI]. The compound exhibits minimal off-target activity against other bromodomain-containing proteins, making it a reference standard for BET inhibition [internal]. Its physical properties (solid, MW 423.9, C22H22ClN5O2, DMSO solubility ≥21.19 mg/mL) support robust experimental workflows. I-BET-762's translational utility spans inflammation, epigenetic regulation, and cancer research.

Biological Rationale

The bromodomain and extra-terminal domain (BET) family proteins, including BRD2, BRD3, BRD4, and BRDT, serve as epigenetic readers that recognize acetylated lysine residues on histones. This recognition regulates transcription of genes involved in inflammation, cell cycle progression, and oncogenesis (Fan et al., 2024). Aberrant BET activity is implicated in various malignancies and inflammatory disorders. Targeting BET proteins with small-molecule inhibitors like I-BET-762 disrupts pathological gene expression, offering a precise approach to modulate disease-relevant pathways. The ability to downregulate LPS-inducible genes and potentiate ferroptosis positions I-BET-762 as a mechanistically validated research tool for dissecting transcriptional regulation and cell death modalities in preclinical models.

Mechanism of Action of I-BET-762

I-BET-762 binds selectively to the acetyl-lysine binding pocket of BET proteins, exhibiting a 2:1 inhibitor:protein binding ratio. This competitive interaction displaces endogenous acetyl-lysine residues, preventing BET recruitment to chromatin and subsequent transcriptional activation of target genes. The compound shows a Kd of 50.5–61.3 nM and an IC50 of 32.5–42.5 nM, measured in biochemical assays under physiological pH at 25°C [product]. Importantly, I-BET-762 displays high selectivity: no significant binding is observed against non-BET bromodomains at concentrations up to 10 μM. Functional assays demonstrate that I-BET-762 downregulates expression of LPS-inducible cytokines and chemokines (e.g., IL-6, TNF-α), and suppresses BRD4-mediated transcriptional programs. In combination with the ferroptosis inducer erastin, I-BET-762 increases intracellular ROS and reduces FSP1 expression, thereby promoting ferroptotic cell death in diverse cancer cell lines (Fan et al., 2024).

Evidence & Benchmarks

• I-BET-762 binds to BET family proteins with a Kd of 50.5–61.3 nM and an IC50 of 32.5–42.5 nM in biochemical binding assays (ApexBio, product page).
• I-BET-762 competitively displaces acetyl-lysine from the BET acetyl-lysine binding pocket, as confirmed by structural and displacement assays (Fan et al., 2024, DOI).
• I-BET-762 treatment significantly enhances erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cancer cell lines, with increased ROS and decreased FSP1 (Fan et al., 2024, DOI).
• Downregulation of LPS-inducible cytokines and chemokines is observed in vitro and in vivo after I-BET-762 administration, demonstrating anti-inflammatory effects (ApexBio, product page).
• No significant off-target inhibition of other bromodomain-containing proteins is detected at concentrations up to 10 μM (ApexBio, product page).
• I-BET-762 shows efficacy in inflammatory disease mouse models, ameliorating disease symptoms following LPS challenge (Fan et al., 2024, DOI).

Applications, Limits & Misconceptions

I-BET-762 is widely used in research applications focused on:

• Epigenetic regulation of gene expression in cancer and inflammation models.
• Investigation of BET protein signaling in transcriptional regulation of LPS-inducible genes.
• Enhancing ferroptosis for preclinical cancer therapy studies.
• Probing anti-inflammatory mechanisms in animal models.

The compound is not approved for clinical use and is limited to laboratory research. Its effects may vary across cell types and contexts, particularly regarding ferroptosis-associated gene modulation. For an in-depth mechanistic perspective extending the present discussion, see "I-BET-762: Unraveling BET Inhibition for Ferroptosis and ...", which offers additional context on transcriptional regulation and translational applications. This article also clarifies recent advances by benchmarking new data on FSP1 and ROS pathways not covered in "I-BET-762: Precision BET Inhibition Fuels Next-Gen Ferrop...".

Common Pitfalls or Misconceptions

• I-BET-762 is not a pan-bromodomain inhibitor: It selectively targets BET family proteins and shows minimal activity against non-BET bromodomains (ApexBio).
• Solubility limitations: The compound is insoluble in water and requires DMSO (≥21.19 mg/mL) or ethanol (≥13.93 mg/mL, with ultrasonic assistance) for dissolution.
• Stability concerns: I-BET-762 solutions degrade over time; prepare fresh aliquots and store at -20°C (ApexBio).
• In vivo use is research-only: I-BET-762 is not licensed for human therapy and should not be used outside controlled preclinical models.
• Cell line-dependent effects: The impact on ferroptosis-associated genes (e.g., FTH1, Nrf2, GPX4, FSP1) varies across different cell lines (Fan et al., 2024).

Workflow Integration & Parameters

Storage and Handling: Store I-BET-762 powder at -20°C. For solution, use DMSO or ethanol (with ultrasonic assistance) and aliquot for single-use to prevent freeze-thaw degradation. Recommended working concentrations range from 1–2 μM for cell-based assays, with higher concentrations used for biochemical binding studies. Prepare solutions immediately prior to use, as stability in solution is time-limited.

Experimental Design: For BET inhibition in cell culture, treat cells with 1–2 μM I-BET-762 for 24–48 hours, monitoring target gene downregulation or cell viability. For ferroptosis studies, combine I-BET-762 (2 μM) with erastin (20 μM) and assess ROS accumulation and FSP1 expression by qPCR or western blot, referencing control and knockdown lines as benchmarks (Fan et al., 2024).

The I-BET-762 product page provides detailed handling and safety data. For advanced workflow strategies, see "I-BET-762: Mechanistic Advances and Strategic Horizons fo...", which expands on integration in epigenetic and inflammatory disease models, complementing the new evidence presented here.

Conclusion & Outlook

I-BET-762 is a rigorously characterized, selective BET inhibitor with validated potency for epigenetic, inflammation, and ferroptosis research. Its precise mechanism—competitive inhibition of the acetyl-lysine binding pocket—enables targeted modulation of disease-relevant transcriptional programs. Recent evidence underscores its translational utility in promoting ferroptosis and suppressing inflammatory gene expression. Researchers should apply I-BET-762 within recommended parameters and remain aware of cell-type specific responses and solubility/stability constraints. Continued study will refine its role in emerging therapeutic paradigms and disease modeling.